Aldeyra's Allergy Drug Misses Endpoint But Company Sees Market Gap
Aldeyra is moving ahead with plans for Phase III trials of its novel allergy drug in the face of a missed Phase IIb endpoint. Its ultimate success could rest on what endpoint the FDA will accept.
You may also be interested in...
Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results
The company announced positive results for reproxalap from its Phase III INVIGORATE trial in allergic conjunctivitis, which may be a good sign for its dry eye disease studies.
In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.